Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B
- 13 April 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 64 (10), 2992-3000
- https://doi.org/10.1007/s10620-019-05614-6
Abstract
Long-term results on hepatitis B virus (HBV) reactivation in patients with resolved infection during anti-cancer therapy are unknown. This study investigated long-term risk and therapeutic endpoints including hepatitis B surface antigen (HBsAg) seroclearance following antiviral therapy in patients developing reactivation of resolved HBV.Keywords
Funding Information
- the Ministry of Science, ICT & Future Planning (NRF-2016R1D1A1B03930457)
This publication has 29 references indexed in Scilit:
- Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B VirusTransplantation and Cellular Therapy, 2011
- Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infectionAlimentary Pharmacology & Therapeutics, 2011
- Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg LossThe Journal of Infectious Diseases, 2011
- Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patientsHepatology, 2010
- Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCTBone Marrow Transplantation, 2010
- Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis BHepatology, 2010
- HBV replication is significantly reduced by IL-6Journal of Biomedical Science, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Inflammation, HCC and sex: IL-6 in the centre of the triangleJournal of Hepatology, 2008
- Kinetics and Risk of De Novo Hepatitis B Infection in HBsAg–Negative Patients Undergoing Cytotoxic ChemotherapyGastroenterology, 2006